{"filings":[{"id":1949883,"accession_number":"0001193125-26-324865","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2026-07-30T11:05:07+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom Q2 revenue $74.3M (+88% YoY); net loss narrows to $17.6M; initiates Phase 3 NERD trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q2 net revenue $74.3M, up 88% YoY and 27% QoQ; operating expenses $63.1M, down 33% YoY.","Net loss $17.6M vs $75.8M in Q2 2025; non-GAAP adjusted net loss nearly zero at $0.1M.","~325,000 VOQUEZNA prescriptions in Q2 (+88% YoY); ~1.7M total to date.","Initiating Phase 3 trial for as-needed VOQUEZNA in NERD; first enrollment expected Q4 2026.","Completed enrollment in Phase 2 EoE trial; topline results expected Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":132575000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1204564,"accession_number":"0001193125-26-278533","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2026-06-23T12:00:06+00:00","items":["8.01"],"status":"ready","headline":"Phathom completes enrollment in Phase 2 EoE trial; topline data expected Q4 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrolled 95 adults at 41 US sites in pHalcon-EoE-201 Phase 2 trial of VOQUEZNA for eosinophilic esophagitis.","Patients randomized 1:1 to VOQUEZNA 20 mg or placebo once daily for 12 weeks; optional open-label extension.","Topline results anticipated in Q4 2026; positive data could lead to FDA discussions on pediatric exclusivity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":581601,"accession_number":"0001193125-26-234379","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2026-05-21T20:01:07+00:00","items":["5.07"],"status":"ready","headline":"Phathom stockholders elect three Class I directors, ratify EY, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Steven Basta, Theodore R. Schroeder, Mark Stenhouse as Class I directors: 42.7M, 42.6M, 41.2M votes for respectively.","Ratified Ernst & Young as independent auditor for FY 2026: 64.5M for, 49,661 against.","Advisory say-on-pay approved: 44.4M for, 2.5M against, 165,675 abstentions.","Broker non-votes of 17.5M on director election and say-on-pay; all proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95405,"accession_number":"0001193125-26-193945","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom Pharma Q1 net rev $58.3M (+104% YoY); maintains FY 2026 op profitability guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net revenues $58.3M vs $28.5M YoY; net loss $30.4M vs $94.3M YoY.","Non-GAAP operating expenses $56.2M, down ~43% YoY; cash and equivalents $180.9M.","~1.35M total VOQUEZNA prescriptions filled to date; Q1 covered prescriptions up 91% YoY.","FY 2026 guidance: net rev $320-345M, non-GAAP op ex $235-255M; op profitability expected Q3 2026.","EoE phase 2 trial (pHalcon-EoE-201) topline results expected late Q4 2026/early Q1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":58301000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108465,"accession_number":"0001193125-26-073377","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom reports Q4 revenue $57.6M, FY2025 revenue $175.1M (+217% YoY); expects operating profitability in Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net revenues $57.6M; FY2025 net revenues $175.1M, a 217% increase over FY2024.","Q4 GAAP net loss narrowed to $21.1M from $74.5M in Q4 2024.","Non-GAAP adjusted net loss for Q4 was $5.7M, improved from $56.4M in Q4 2024.","Expects operating profitability beginning Q3 2026 and for FY2026; cash flow positivity in 2027.","Completed $130M equity offering Jan 2026; modified term loan to $175M principal, extended maturity to Feb 2029; pro forma cash ~$190M."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":175110000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108464,"accession_number":"0001193125-26-007660","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phathom Pharmaceuticals prices $130M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["6,875,000 shares of common stock at $16.00/share and pre-funded warrants for 1,250,078 shares at $15.999/warrant.","Gross proceeds approximately $130M; underwriters have 30-day option for additional 1,218,761 shares.","Net proceeds for general corporate purposes, including working capital and R&D.","Offering expected to close on/about January 9, 2026; Guggenheim Securities and Cantor are joint bookrunners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108463,"accession_number":"0001193125-26-006266","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom reports preliminary Q4 2025 revenue $57-58M; full year $174.5-175.5M; VOQUEZNA surpasses 1M prescriptions","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net revenues expected ~$57-58M; full year 2025 net revenues ~$174.5-175.5M.","GAAP operating expenses Q4: ~$59-61M; non-GAAP (excl. stock-based comp) ~$51-53M.","Cash and equivalents ~$130M as of 12/31/25; net cash usage in Q4 ~$6M.","VOQUEZNA products surpassed 1 million prescriptions dispensed in U.S. during Q4.","Operating profitability (excl. stock-based comp) anticipated in second half of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":175110000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124900,"accession_number":"0001193125-25-263534","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Phathom Pharmaceuticals doses first patient in Phase 2 EoE trial of VOQUEZNA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 2 pHalcon EoE-201 trial evaluating VOQUEZNA (vonoprazan) for eosinophilic esophagitis in adults.","Part 1: 80 adults with confirmed EoE and dysphagia randomized 1:1 to VOQUEZNA 20 mg or placebo once daily for 12 weeks.","Part 2: open-label 12-week extension where all patients receive VOQUEZNA 20 mg daily.","Topline results from primary and secondary endpoints are anticipated in 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124899,"accession_number":"0001193125-25-257382","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom Q3 revenue $49.5M, up 25% QoQ; net loss $30M; FY guidance raised to $170-175M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue of $49.5M in Q3 2025, up 25% from Q2 and from $16.4M in Q3 2024.","Net loss narrowed to $30.0M from $85.6M in Q3 2024; non-GAAP adjusted net loss $11.2M.","Full-year 2025 revenue guidance raised to $170-175M; expects operating profitability in 2026.","Over 790,000 cumulative VOQUEZNA prescriptions filled; Q3 filled prescriptions up 28% QoQ.","Appointed Sanjeev Narula as CFO/Chief Business Officer and Nancy Phelan as SVP Marketing."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":117526000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124898,"accession_number":"0001193125-25-250611","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Phathom publishes Phase 3 NERD data showing VOQUEZNA improves nocturnal GERD symptoms","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At week 4, VOQUEZNA 10 mg and 20 mg achieved 59.9% and 56.4% heartburn-free nights vs 43.3% placebo (nominal p<0.0001).","Median heartburn-free nights: 70.4% (10 mg), 71.0% (20 mg), 45.5% (placebo) over 4 weeks.","Separation from placebo observed after first dose: 45.3% (10 mg) and 52.4% (20 mg) heartburn-free night vs 32.1% placebo.","Symptom relief sustained through 20-week active extension; median heartburn-free nights remained above 70%.","VOQUEZNA generally well tolerated; most common AEs (≤5%) included URI, sinusitis, influenza, UTI, nausea."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124897,"accession_number":"0001193125-25-230984","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Phathom Pharmaceuticals appoints Sanjeev Narula as CFO and Business Officer effective Oct 6, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sanjeev Narula named Chief Financial and Business Officer; replaces Robert Breedlove as principal financial officer.","Initial base salary of $550,000 with annual target bonus of 50% of base salary.","Receives stock options for 200,000 shares (4-year vest) and 144,000 RSUs (3-year annual vest).","Narula previously CFO of Intra-Cellular Therapies and Viatris; brings extensive biopharma finance experience.","Robert Breedlove continues as Vice President, Finance and principal accounting officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141612,"accession_number":"0001193125-25-174943","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom Q2 revenue $39.5M, up from $7.3M YoY; 580k+ VOQUEZNA scripts filled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $39.5M in Q2 2025 vs $7.3M in Q2 2024; net loss $75.8M vs $91.4M YoY.","Over 580k total VOQUEZNA prescriptions filled (+49% since May 1); ~173k in Q2 (36% sequential growth).","10-year NCE exclusivity for VOQUEZNA 10mg/20mg tablets through May 2032; generic entry unlikely before 2033.","Full-year 2025 revenue guidance $165M-$175M; expects non-GAAP OpEx <$60M in Q3 and <$55M in Q4.","Appointed Anne Marie Cook as Chief Legal Officer and Corporate Secretary."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":68023000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159485,"accession_number":"0001193125-25-141119","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA Orange Book corrected; VOQUEZNA NCE exclusivity confirmed through May 2032","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA updated Orange Book to show full 10-year NCE exclusivity for VOQUEZNA (vonoprazan) 10 mg and 20 mg tablets.","Corrected listing confirms exclusivity runs through May 3, 2032, aligning with statutory requirements.","Phathom says this reinforces the long-term commercial runway for its first-in-class product.","NCE exclusivity prevents generic competition for the full 10-year period from approval date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159484,"accession_number":"0001193125-25-137800","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"PHAT shareholders elect two directors, ratify EY, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Heidi Kunz elected Class III director with 34,023,182 for, 451,384 withheld; James Topper with 26,884,171 for, 7,590,395 withheld.","Ernst & Young LLP ratified as auditor for fiscal 2025: 51,670,346 for, 177,785 against, 53,817 abstentions.","Say-on-pay approved on non-binding advisory basis: 24,584,781 for, 8,704,739 against, 1,185,046 abstentions, 17,427,382 broker non-votes.","Say-on-frequency set to every 1 year with 30,665,967 votes for, 21,543 for 2 years, 2,611,188 for 3 years, 1,175,868 abstentions.","Company will hold annual advisory votes on executive compensation until next required say-on-pay vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159483,"accession_number":"0001193125-25-137094","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA grants Phathom citizen petition; VOQUEZNA exclusivity extended to May 2032","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Phathom's 2024 citizen petition to correct Orange Book for VOQUEZNA (vonoprazan) tablets.","VOQUEZNA will benefit from the 10-year NCE*GAIN exclusivity originally awarded to VOQUEZNA Triple Pak and Dual Pak.","FDA will update Orange Book to reflect exclusivity extending through May 3, 2032 (previously May 3, 2027).","Decision protects VOQUEZNA from generic competition for an additional 5 years under FDA's umbrella policy.","VOQUEZNA was not itself designated as a QIDP, but the exclusivity attaches to the active moiety vonoprazan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159482,"accession_number":"0001193125-25-108726","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom Q1 net revenue $28.5M, net loss $94.3M; cuts costs, exec changes, targets 2026 profit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $28.5M (up from $1.9M YoY); net loss $94.3M ($77.1M non-GAAP adjusted).","Over 390k VOQUEZNA prescriptions filled; ~127k in Q1, up ~8% sequentially despite seasonal headwinds.","Cost reduction: cut 2025 opex by $60-70M, reduce headcount ~6%, pause EoE trial, target Q4 spend <$55M.","CEO restructuring: new SVP Sales from Intra-Cellular; COO, CCO, CFO exit; Ted Schroeder on Board.","Citizen Petition filed Dec 2024 for 10-year NCE exclusivity; FDA response due within 180 days."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":28519000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159481,"accession_number":"0001193125-25-082089","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Phathom Pharmaceuticals appoints Theodore R. Schroeder to board, effective April 16, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Schroeder appointed as Class I director, term expiring at 2026 annual meeting; will serve on audit committee.","Received option for 35,000 shares and 21,000 RSUs, both vesting over three years; plus cash compensation.","Former CEO of Nabriva Therapeutics, co-founded Cadence Pharmaceuticals (bought by Mallinckrodt), held senior roles at Elan, Dura, and Bristol-Myers Squibb.","Board determined Schroeder meets Nasdaq independence standards; no related party transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159480,"accession_number":"0001193125-25-069748","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CEO transition at Phathom: Steven Basta appointed, Terrie Curran resigns effective March 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven Basta appointed CEO, President and Class I director effective April 1, 2025; Terrie Curran resigned for personal reasons.","Basta receives $700k base salary, 70% target bonus, and initial option grant of 1,085,000 shares vesting over 4 years.","Basta also granted 360k stock-price-hurdle PSUs and 180k revenue-based PSUs (target) under new inducement plan.","Curran severance includes base salary through June 30, 2026, 2025 target bonus lump sum, COBRA, and accelerated vesting.","Board adopted 2025 Employment Inducement Incentive Award Plan reserving 2,500,000 shares without stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177861,"accession_number":"0001193125-25-047882","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom Pharma Q4 revenue $29.7M; VOQUEZNA prescriptions up 81% QoQ","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 net revenue $55.3M from VOQUEZNA launch; Q4 revenue $29.7M (81% increase vs Q3).","Over 300,000 filled prescriptions launch-to-date, up ~110% since last earnings report.","Q4 net loss $74.5M; non-GAAP adjusted net loss $56.4M vs $46.0M in prior year Q4.","SG&A expenses rose to $290.7M in FY2024 vs $117.9M in FY2023 due to commercial buildout.","Phase 2 EoE trial for VOQUEZNA to begin enrollment in Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194570,"accession_number":"0001193125-24-274876","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Phathom files Citizen Petition to correct VOQUEZNA Orange Book exclusivity to May 2032","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Petition requests FDA correct VOQUEZNA tablet listings to reflect 10-year NCE exclusivity ending May 3, 2032.","Exclusivity stems from GAIN Act extension on vonoprazan, already applied to VOQUEZNA DUAL/TRIPLE PAK approved May 2022.","FDA must respond within 180 days; may approve, deny, or provide tentative response.","Corrected listing would block ANDA or 505(b)(2) submissions referencing vonoprazan until expiry.","Phathom expects CP docket to appear on regulations.gov in coming days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194569,"accession_number":"0001193125-24-252642","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom Q3 net revenues $16.4M, up >120% QoQ; net loss $85.6M; VOQUEZNA prescriptions exceed 143k launch-to-date","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $16.4M for Q3 2024 (vs $7.3M Q2 2024); no revenues in Q3 2023.","Over 143,000 prescriptions for VOQUEZNA products filled launch-to-date (138% increase since last quarterly report).","Net loss $85.6M vs $43.2M in Q3 2023; non-GAAP adjusted net loss $67.9M vs $30.8M.","Commercial access expanded to >80% of U.S. commercial lives (est. 120M covered lives).","R&D expenses down to $8.7M; SG&A up to $76.1M due to commercial buildout."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":25588000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210893,"accession_number":"0001193125-24-202879","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phathom Pharmaceuticals prices $130M stock/warrant offering; net proceeds ~$121.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["8,695,652 shares at $11.50/share and pre-funded warrants for 2,608,922 shares at $11.499/warrant.","Gross proceeds ~$130M; net proceeds ~$121.7M after underwriting discounts and expenses.","Offering expected to close August 20, 2024; use proceeds for commercialization and vonoprazan clinical development.","Joint bookrunners: Evercore ISI, Stifel, Guggenheim; co-managers: H.C. Wainwright, Needham, Craig-Hallum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210892,"accession_number":"0001193125-24-196506","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom Q2 revenue $7.3M, prescriptions up 184%; VOQUEZNA gets FDA approval for Non-Erosive GERD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $7.3M in Q2 2024 vs $1.9M in Q1 2024; no Q2 2023 revenue due to launch in late 2023.","Over 122,000 cumulative prescriptions written (184% increase from 43,000); over 60,000 filled (240% from 17,500).","FDA approved VOQUEZNA 10mg for Non-Erosive GERD on July 18; commercial coverage now >116M lives (77% of US commercial).","Net loss $91.4M; non-GAAP adjusted net loss $73.3M; SG&A rose to $75.9M on launch commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":9236000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210891,"accession_number":"0001193125-24-180750","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Phathom gets FDA approval for VOQUEZNA to treat heartburn in Non-Erosive GERD","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved VOQUEZNA (vonoprazan) 10 mg tablets for relief of heartburn associated with Non-Erosive GERD in adults.","This is the third FDA approval for VOQUEZNA; also approved for Erosive GERD and H. pylori eradication.","Approximately 45 million US adults have Non-Erosive GERD; about 15 million treated with prescription medicine annually.","Non-Erosive GERD is the largest GERD category, characterized by reflux symptoms without esophageal erosions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229316,"accession_number":"0001193125-24-147017","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Phathom stockholders elect three Class II directors; ratify E&Y as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Cola (24.1M for), Karbe (25.0M for), Parikh (21.3M for) with 10.8M broker non-votes each.","Ratified Ernst & Young as independent auditor for fiscal 2024: 37.9M for, 124.6K against, 1.1K abstain.","New non-employee directors get initial grant of 21,000 RSUs and options to purchase 35,000 shares.","Annual director equity grant set at 10,500 RSUs and options for 17,500 shares; cash retainers unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229315,"accession_number":"0001193125-24-134793","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom posts Q1 net loss $82.9M, revenue $1.9M; VOQUEZNA prescriptions top 17,500","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss GAAP $82.9M (non-GAAP adj. net loss $64.8M) vs $37.8M loss Q1 2023; revenue $1.9M from VOQUEZNA launch.","Over 17,500 prescriptions dispensed launch-to-date (+361% vs last quarterly report); >3,800 prescribers.","SG&A expenses $62.0M (up from $18.6M YoY) reflecting commercial infrastructure build and marketing.","Cigna added VOQUEZNA to formularies; commercial coverage now ~48% of U.S. commercial lives (~72M covered).","FDA PDUFA date July 19, 2024 for NERD indication; Phase 3 NERD and Phase 2 EoE studies planned later in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":1912000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247894,"accession_number":"0001193125-24-061512","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom reports Q4/FY2023 results; VOQUEZNA launch nets $0.7M revenue, cash runway extended to 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net revenue $0.7M from VOQUEZNA launch; cumulative prescriptions over 14,000 as of Feb 23, 2024.","Expanded term loan facility up to $300M with more favorable terms; access to $160M additional; cash runway through 2026.","Express Scripts added VOQUEZNA to formularies; ~60M commercial lives covered (~38% of U.S. commercial).","FDA accepted NDA for Non-Erosive GERD; PDUFA July 19, 2024; launch expected upon approval.","Net loss Q4 $79.6M ($46M non-GAAP adjusted); G&A up due to commercial build and stock-based comp."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247893,"accession_number":"0001193125-24-032946","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Express Scripts adds VOQUEZNA to national formularies for commercial plans","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Express Scripts, a leading U.S. PBM, added VOQUEZNA to its national formularies for commercial plans, effective immediately.","Formulary placement offers access to VOQUEZNA with a single step through a generic proton pump inhibitor (PPI).","Expanded formulary access may drive uptake of Phathom's approved product VOQUEZNA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265327,"accession_number":"0001193125-23-296630","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Phathom amends bylaws to adopt universal proxy rules and enhance stockholder nomination disclosures","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended bylaws require compliance with SEC Rule 14a-19 for proxy solicitations supporting non-Board nominees.","Enhanced disclosure requirements for stockholders nominating directors or submitting proposals at meetings.","Changes effective December 13, 2023; also includes technical and modernizing updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265326,"accession_number":"0001193125-23-294942","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Phathom Pharma amends loan agreement, boosts facility to $300M, lowers rate","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Fourth Amendment with Hercules Capital increases aggregate loan from $200M to $300M; $40M of Tranche 2 funded at closing.","New tranches 2-6 total up to $160M undrawn; maturity extended from October 2026 to December 2027.","Cash interest reduced from 10.75% to 9.85% (capped at 10.35%); PIK interest cut from 3.35% to 2.15%.","Minimum cash covenant lowered to 20% of outstanding principal; revenue performance covenant starts September 30, 2024.","Revenue covenant waived if cash >50% (later 35%) of outstanding or market cap exceeds $900M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265325,"accession_number":"0001193125-23-289582","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2023-12-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Phathom's NDA for VOQUEZNA in Non-Erosive GERD accepted by FDA; PDUFA date July 19, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted NDA for VOQUEZNA (vonoprazan) for daily heartburn treatment in Non-Erosive GERD.","Standard 10-month review assigned; PDUFA target action date is July 19, 2024.","Plans to initiate an additional Phase 3 study in 2024 evaluating VOQUEZNA for As Needed episodic heartburn relief.","No PPIs are currently approved for as-needed use in Non-Erosive GERD, a potential differentiation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265324,"accession_number":"0001193125-23-283719","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2023-11-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Phathom launches VOQUEZNA for erosive GERD; H. pylori regimens expected mid-Dec.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VOQUEZNA (vonoprazan) now available in 30-count bottles for erosive GERD treatment and heartburn relief.","Phase 3 trial: 93% healing rate at Week 8 with VOQUEZNA 20mg vs 85% for lansoprazole 30mg.","VOQUEZNA 10mg superior to lansoprazole 15mg at maintaining healing at 6 months (79% vs 72%).","No mealtime dosing required; prescriptions fillable at major retail pharmacies and via BlinkRx.","VOQUEZNA TRIPLE PAK and DUAL PAK for H. pylori expected commercially by mid-December 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265323,"accession_number":"0001193125-23-274082","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom Q3 net loss $43.2M; VOQUEZNA FDA approved for Erosive GERD; Dec launch","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $43.2M in Q3 2023 vs $51.1M in Q3 2022; includes $6.1M stock-based compensation.","Cash $213.7M at Sep 30; $175M from revenue interest financing plus $100M Hercules loan available.","FDA approved VOQUEZNA (vonoprazan) for Erosive GERD in Nov 2023; launch expected Dec 2023.","NDA submitted for vonoprazan as daily Non-Erosive GERD treatment in Sep 2023; FDA action Q3 2024.","Phase 3 As Needed NERD trial to start in 2024; cash expected to fund ops through end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265322,"accession_number":"0001193125-23-268319","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA approves Phathom's VOQUEZNA for Erosive GERD; triggers $175M payment","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved VOQUEZNA (vonoprazan) for healing, maintenance, and heartburn relief in Erosive GERD.","Phase 3 PHALCON-EE trial showed 93% healing rate at Week 8 for VOQUEZNA 20mg vs 85% for lansoprazole.","VOQUEZNA demonstrated superiority in moderate-to-severe patients (70% vs 53% at Week 2).","Approval triggers a $175M non-dilutive payment from Revenue Interest Financing Agreement.","VOQUEZNA expected to launch in US in December 2023; marketed exclusively by Phathom."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265321,"accession_number":"0001193125-23-265692","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA approves reformulated vonoprazan for H. pylori; launch expected Dec 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved prior approval supplements for reformulated vonoprazan tablets in VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK for H. pylori infection in adults.","Product expected to be available in the U.S. in December 2023 and marketed exclusively by Phathom.","H. pylori infects an estimated 115 million individuals in the U.S.; 36% of the U.S. population estimated to be infected.","Phathom planning combined U.S. commercial launch of H. pylori regimens and Erosive GERD vonoprazan, if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282539,"accession_number":"0001193125-23-241941","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Phathom submits NDA to FDA for vonoprazan as daily Non-Erosive GERD treatment","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NDA for vonoprazan as daily treatment for Non-Erosive GERD in adults submitted to FDA, supported by Phase 3 PHALCON-NERD-301 study.","Primary endpoint met: 45% (10 mg) and 44% (20 mg) heartburn-free days vs 28% placebo (p<0.0001).","20-week extension study showed 61-63% heartburn-free days for vonoprazan doses.","FDA review expected 10 months; potential Q3 2024 U.S. launch if approved.","Vonoprazan under review for Erosive GERD with PDUFA date Nov 17, 2023; Q4 2023 launch planned if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282538,"accession_number":"0001193125-23-216611","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2023-08-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Phathom submits 6-month stability data for vonoprazan NDA; NVP impurity controlled below limit","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted 6-month stability data for reformulated vonoprazan tablets to FDA for Erosive GERD NDA.","NVP (nitrosamine impurity) kept >10-fold below acceptable daily intake limit of 96 ng/day (2.4 ppm) through 6 months.","PDUFA goal date for NDA resubmission (Class 2) is November 17, 2023.","If approved, combined US launch for Erosive GERD and H. pylori planned for Q4 2023.","Data addresses CRL issued Feb 2023 regarding specifications/controls for NVP impurity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282537,"accession_number":"0001193125-23-209005","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom Q2 net loss $41.0M; PDUFA dates Oct/Nov 2023 for VOQUEZNA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $41.0M in Q2 2023, improved from $50.9M in Q2 2022.","Cash $248.8M at June 30; $100M available from Hercules on Oct 1, $175M upon Erosive GERD approval.","FDA PDUFA dates: Oct 30 for VOQUEZNA H. pylori packs; Nov 17 for Erosive GERD NDA.","Completed public offering May 2023 with $141.4M net proceeds.","Phase 3 PHALCON-NERD-301 completed; regulatory submission for Non-Erosive GERD on track H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282536,"accession_number":"0001193125-23-188097","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2023-07-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Phathom completes stock option exchange; 99.2% of eligible options surrendered for RSUs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2,406,622 options surrendered (~99.2% of eligible) for 1,203,341 new RSUs at 2-for-1 ratio.","Terrie Curran exchanged 400,000 options for 200,000 RSUs; Azmi Nabulsi exchanged 220,000 for 110,000 RSUs.","New RSUs vest in three equal annual installments; program expired July 14, 2023.","Options were deeply underwater; exchange intended to retain employees and align incentives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301778,"accession_number":"0001193125-23-167476","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Phathom launches voluntary stock option exchange for RSUs at 2-for-1 ratio","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eligible employees and consultants can exchange outstanding stock options for RSUs at a 2-for-1 ratio (one RSU per two options).","Option exchange commenced June 15, 2023; participants must remain employed through expiration.","Non-employee board members are excluded from participation.","Exchange is made under the 2019 Incentive Award Plan via a tender offer statement on Schedule TO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301777,"accession_number":"0001193125-23-164930","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2023-06-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA accepts Phathom's vonoprazan NDA resubmission for Erosive GERD; PDUFA date Nov 17, 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA acknowledged NDA resubmission for vonoprazan, a PCAB, as complete response to the February 2023 CRL.","Classified as a Class 2 resubmission with a PDUFA goal date of November 17, 2023.","Resubmission included three months stability data of reformulated tablets to support commercial shelf life.","Additional stability data will be provided during review as previously agreed with the FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301776,"accession_number":"0001193125-23-156713","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2023-05-30T23:59:59+00:00","items":["5.03","5.07","8.01","9.01"],"status":"ready","headline":"Phathom shareholders approve officer liability amendment, elect directors, ratify auditor; board updates director comp","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment eliminating personal liability of officers for monetary damages for breach of fiduciary duty (effective May 26, 2023).","Terrie Curran and Mark Stenhouse elected as Class I directors for three-year terms; votes for: Curran 32.2M, Stenhouse 29.0M.","Ernst & Young ratified as independent auditor for 2023 with 38.9M votes for (99.9%).","Board updated non-employee director compensation: new directors get 18K RSUs + options for 30K shares; annual grants of 9K RSUs + options for 15K shares.","Proposal to limit officer liability passed with 30.1M votes for, 2.1M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301775,"accession_number":"0001193125-23-152946","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2023-05-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phathom prices public offering of 11.125M shares at $11.75/share for ~$130.7M gross","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 11,125,000 shares at $11.75/share; gross proceeds ~$130.7M.","Underwriters have 30-day option to purchase up to 1,668,750 additional shares.","Net proceeds ~$122.4M ($140.8M if option exercised) to fund vonoprazan clinical dev., pre-commercial, and working capital.","Offering expected to close May 26, 2023; Jefferies and Evercore ISI act as joint bookrunners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301774,"accession_number":"0001193125-23-151785","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2023-05-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Phathom resubmits NDA for vonoprazan for erosive GERD with stability data controlling nitrosamine impurity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Resubmitted vonoprazan NDA for erosive GERD to FDA after February 2023 Complete Response Letter.","Stability data from six reformulated batches show NVP levels >10-fold below 96 ng/day intake limit through 3 months.","NDA classified as Class 2 resubmission with 6-month review; 6-month stability data to be provided during review.","If approved, combined U.S. commercial launch for erosive GERD and H. pylori indications planned for Q4 2023.","Phase 3 PHALCON-EE trial enrolled 1,024 patients; compared vonoprazan to lansoprazole."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301773,"accession_number":"0001193125-23-140078","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom Q1 net loss $37.8M, on track to resubmit Erosive GERD NDA this quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $37.8M vs $40.7M YoY; operating expenses 36% lower than prior quarter due to cost controls after launch delay.","Cash $129.6M at Mar 31, 2023; additional $100M term loan available, $175M upon FDA approval of VOQUEZNA for Erosive GERD.","On track to resubmit Erosive GERD NDA this quarter; potential FDA approval and U.S. launch for Erosive GERD and H. pylori in Q4 2023.","Ph3 PHALCON-NERD-301 trial met primary endpoint; regulatory submission for Non-Erosive GERD expected H2 2023.","Coverage secured for 60% of commercial lives for VOQUEZNA TRIPLE PAK and DUAL PAK for H. pylori."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301772,"accession_number":"0001193125-23-090354","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2023-04-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Phathom provides regulatory update on path to resubmit EE NDA in Q2 2023; launch expected Q4 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Met with FDA; CRLs solely related to nitrosamine impurity NVP; mitigation includes minor tablet reformulation.","Stability data shared with FDA; anticipates resubmitting EE NDA in Q2 2023, with combined EE/H. pylori launch in Q4 2023.","Also plans to submit PAS for H. pylori; FDA action expected in Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321531,"accession_number":"0001193125-23-052344","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phathom reports Q4 net loss $55M; FDA meeting in March for vonoprazan resubmission","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2022 $55.0M vs $35.8M Q4 2021; full year net loss $197.7M vs $143.9M.","Cash $155.4M at Dec 31, 2022; additional $100M available under Hercules term loan.","FDA meeting scheduled March 2023 to discuss stability data and resubmission for erosive GERD and H. pylori NDAs.","Positive Phase 3 PHALCON-NERD-301 met primary endpoint (p<0.0001) for vonoprazan in non-erosive GERD.","Commercial launch on hold due to nitrosamine impurity; mitigation measures in place."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321530,"accession_number":"0001193125-23-030011","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2023-02-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Phathom receives FDA complete response letters for vonoprazan NDAs due to nitrosamine impurity","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CRL for erosive esophagitis NDA and H. pylori post-approval supplement, citing impurity N-nitroso-vonoprazan (NVP).","FDA requests additional stability data showing NVP remains below acceptable intake throughout shelf life; no other deficiencies.","Phathom implemented mitigation measures and expects to meet with FDA in Q1 2023 to discuss resubmission timeline.","This follows January 2023 announcement; delays potential approval and commercial launch of vonoprazan products."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321529,"accession_number":"0001193125-23-004049","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Phathom announces positive Ph3 NERD-301 topline results for vonoprazan; both doses met primary endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vonoprazan 10 mg and 20 mg both achieved significantly greater 24-hour heartburn-free days vs placebo (46.4% and 46.0% vs 27.5%; p<0.0001).","Median percentage of heartburn-free days: 48.3% (10 mg), 46.7% (20 mg), 17.0% (placebo).","Safety profile comparable to placebo; most common AE was nausea (2.3% 10 mg, 3.1% 20 mg, 0.4% placebo).","Blinded 20-week long-term extension ongoing; full results expected later in 2023.","Discussions with FDA ongoing regarding separate Phase 3 trial for on-demand dosing in NERD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321528,"accession_number":"0001193125-23-000749","cik":1783183,"company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","form_type":"8-K","filed_at":"2023-01-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA delays action on Phathom's vonoprazan EE NDA; nitrosamine impurity data required, launch pushed past Q1 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA will not act by Jan 11, 2023 PDUFA date for vonoprazan erosive esophagitis NDA.","Acceptable daily intake for nitrosamine impurity NVP set at 96 ng/day; additional stability data required.","Phathom no longer expects product launches for H. pylori or EE in Q1 2023.","Company is generating additional stability data and discussing nature/extent with FDA.","Previously identified NVP impurity in commercial batches delays both indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":847805740.5819367,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-01-03T23:59:59+00:00|321528"}